RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a Sector Perform rating for Beam Therapeutics and maintained a $27 price target.
September 19, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has reiterated its Sector Perform rating for Beam Therapeutics, maintaining a $27 price target. This suggests a neutral outlook on the stock.
The reiteration of a Sector Perform rating and maintenance of the $27 price target by RBC Capital indicates a neutral stance on Beam Therapeutics. This suggests that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100